Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Sreeraj Vasudevan, Anu Korula, Lingaraj Nayak, Mithun Abraham, Alok Shetty, Parathan Karunakaran, Abhilash Menon, Prasanth Ganesan, Gaurav Prakash, Nishil Gowda, Chepsy Philip, Rayaz Ahmed, Sridharan Srinivasan, Prasanna Samuel, Omprakash Karunamurthy, Chandran Nair, Manju Sengar, Vikram Mathews

Blood (2025) 146 (Supplement 1): 7154.

https://doi.org/10.1182/blood-2025-7154

Published: 2025

Journal Articles

Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium

Mithun Abraham Prakash, Lingaraj Nayak, Chandran Nair, Prasanth Ganesan, Dinesh Bhurani, Santhosh Devadas, Sreeraj Vasudevan, Sharat Damodar, M. Joseph John, Punit Jain, Prasanna Samuel, Omprakash Karunamurthy, Sridharan Srinivasan, Vikram Mathews, Manju Sengar, Anu Korula

Blood (2025) 146 (Supplement 1): 7133.

https://doi.org/10.1182/blood-2025-7133

Published: 2025

Journal Articles

Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges

Blood (2025) 146 (Supplement 1): 6321.

https://doi.org/10.1182/blood-2025-6321

Published: 2025

Journal Articles

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Blood (2025) 146 (Supplement 1): 6304.

https://doi.org/10.1182/blood-2025-6304

Published: 2025

Journal Articles

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Blood (2025) 146 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2025-2829

Published: 2025

Journal Articles

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival

Blood (2025) 146 (Supplement 1): 8049.

https://doi.org/10.1182/blood-2025-8049

Published: 2025

Journal Articles

Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship

Sushil Selvarajan, Uday Kulkarni, Ramachandran Shaji, Aby Abraham, Anu Korula, Sharon Lionel, Ganesh Jammula, Biju George, Saurabh Agarwal, Vikram Mathews

Blood (2025) 146 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2025-1730

Published: 2025

Journal Articles

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Sameer Melinkeri, Rahul Bhargava, Neeraj Siddarthan, Dr Dinesh Bhurani, Jayachandran P.K., Esha Kaul, Prashant Mehta, Hari Menon, Bhausaheb Bagal, Kunal Goyal, Prakash Shekhawat, Pavan Kumar Boyella, Rakesh Boya, Ram Abhinav, Rayaz Ahmed, Anil Aribandi, Ashwin V Nair, Chandran Nair, Harish Palaparthi, Lingaraj Nayak, Pawan Singh, Priyanshi Pachauri, Rajat Bhattacharya, Rajiv Kumar, Ranjit Sahoo, Sharat Damodar, Vikram Mathews, Vasu Babu Goli, Abhishek Charan, Ajay Gupta, Amul Kapoor, Anupam Chakrapani, Ashish Bakshi, Bijay Prabhakaran Nair, Bilal Kazi, Debranjani Chattopadhyay, Ganesh S. Jaishetwar, Kaushal Kalra, Kishore Kumar, Lekshmon K.S, Madhav Danthala, Mallikarjun Kalashetty, Narendra Anukonda, Naveen Gupta, Nivedita Dhingra, Padmaja Lokireddy, Prasad Narayanan, Parathan Karunakaran, Prasanth Ganesan, Punit Jain, Priyanka Samal, Ramaswamy N.V., Rajan Kapoor, Shyam Aggarwal, Roy J Palatty, Sainath Bhethanabhotla, Sachin Almel, Santhosh Devadas, Sivakumaran Janakiraman, Sudeep V, Sreeraj Vasudevan, Sameer Tulpule, Suraj Chiraniya, Vijay Patil, Sumita Chaudhry, T Raja, Sunu Cyriac, Shishir Seth, Chezhian Subash, Varun Rajan, Alok Shetty, Vishwanath Sathyanarayanan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayashree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2025-6288

Published: 2025

Journal Articles

Clinico-pathological profile and treatment patterns of immune mediated aplastic anemia in resource constrained settings – an analysis from the aplastic anemia registry of India

Biju George, Arihant Jain, Neeraj Sidharthan, Tuphan Dolai, Rabindra Jena, Chandrakala Shanmukhaiah, Shashikant Apte, Priyanka Samal, Alka Khadwal, Monisha Harimadhavan, Raveen Raj, Rajib De, Dr PRAKAS KUMAR Mandal, Sudha Sethy, Nutan Joshi, Aby Abraham, Pankaj Malhotra, Vikram Mathews

Blood (2025) 146 (Supplement 1): 6253.

https://doi.org/10.1182/blood-2025-6253

Published: 2025

Journal Articles

Higher busulfan cumulative exposure predicts better thalassemia-free survival in patients with beta thalassemia undergoing HCT with busulfan-cyclophosphamide containing conditioning regimen

Poonkuzhali Balasubramanian, Rachel Renji, Jayachitra Aadi, Aswin PAI, Rajesh Nagarajan, Hemamalini Suresh, John Panetta, Kavitha Lakshmi, Eunice Edison, Sujith Karumathil, Aby Abraham, Anu Korula, Uday Kulkarni, Vikram Mathews, Biju George

Blood (2025) 146 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2025-4211

Published: 2025

Journal Articles

Long-term imatinib therapy leads to significant reduction in GFR

Sanjeevan Sharma, Rajan Kapoor, Kundan Mishra, Aby Abraham, Shouriyo Ghosh, Arihant Jain, Pankaj Malhotra, Prashant Parameswaran, Dinesh Bhurani, Sreeraj Vasudevan, Vikram Mathews, Omprakash Karunamurthy, Manju Sengar

Blood (2025) 146 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2025-2005

Published: 2025

Journal Articles

Role of fludarabine exposure on post-transplant outcomes in high-risk β-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning

Rachel Renji, Aswin PAI, Nayanthara Bijukumar, Ezhilpavai Mohanan, Sujith Karumathil, Uday Kulkarni, John Panetta, Kavitha Lakshmi, Eunice Edison, Aby Abraham, Biju George, Anu Korula, Vikram Mathews, Poonkuzhali Balasubramanian

Blood (2025) 146 (Supplement 1): 2419.

https://doi.org/10.1182/blood-2025-2419

Published: 2025

Journal Articles

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Atharva Karulkar, Hasmukh Jain, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Neeraj Siddarthan, Pavan Kumar Boyella, Sanket Shah, Sameer Melinkeri, Anshul Gupta, Prashant Mehta, Chandran Nair, Dinesh Bhurani, Akshay Lahoti, Anupam Chakrapani, Balakrishna Padate, Prakash Shekhawat, Priyanka Samal, Rajat Bajaj, Rumesh Chandar, Padmaja Lokireddy, Anil Aribandi, Bhausaheb Bagal, Girish Badarkhe, Jayachandran P.K., Kripa Bajaj, Nataraj KS, Nishad Dhakate, Rajan Kapoor, Rahul Bhargava, Sameer Tulpule, Sharat Damodar, Sunil Gupta, Suraj Chiraniya, Suvir Singh, Rajasekar Thirugnanam, Vasu Babu Goli, Vikram Mathews, Esha Kaul, Krishna Reddy Golamari, Kannan Subramanian, Lingaraj Nayak, Alok Shetty, Aditya Murali, Punit Jain, Rajat Bhattacharyya, Rakesh Boya, Ram Abhinav, Velu Nair, Hari Menon, Monisha Harimadhavan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayshree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 1076.

https://doi.org/10.1182/blood-2025-1076

Published: 2025

Journal Articles

Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Palani Hamenth Kumar, Arun Kumar Arunachalam, Mohammed Yasar, Phaneendra Venkateswara Rao Datari, Uday Kulkarni, Sushil Selvarajan, Anu Korula, Aby Abraham, Biju George, Vikram Mathews

Blood (2024) 144 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2024-201902

Published: 2024

Journal Articles

Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Anu Korula, Hasmukh Jain, Prasanth Ganesan, Uday Kulkarni, Prasanna Samuel, Manju Sengar, Vikram Mathews

Blood (2024) 144 (Supplement 1): 3055.1.

https://doi.org/10.1182/blood-2024-204488

Published: 2024

Journal Articles

Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose Intensification

Aswin Anand Pai, John C Panetta, Nayanthara Bijukumar, Rachel Mariam Renji, Manoj A, Agila Jayaraman, Sujith Karumathil, Anu Korula, Sushil Selvarajan, Alok Srivastava, Aby Abraham, Vikram Mathews, Biju George, Uday Kulkarni, Poonkuzhali Balasubramanian

Blood (2024) 144 (Supplement 1): 2150.

https://doi.org/10.1182/blood-2024-203105

Published: 2024

Journal Articles

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

Blood (2024) 144 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2024-203645

Published: 2024

Journal Articles

EASIX d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Aswin Anand Pai, Nieshanth Parthiban, Nayanthara Bijukumar, Rachel Mariam Renji, Manoj A, Sujith Karumathil, Kavitha M Lakshmi, Sushil Selvarajan, Anu Korula, Fouzia NA, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George, Uday Kulkarni, Poonkuzhali Balasubramanian

Blood (2024) 144 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2024-201901

Published: 2024

Journal Articles

Patterns of Care and Outcomes of Adults ≥ 40 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Multicenter Registry Analysis from India

Punit Jain, Hasmukh Jain, Rup Jyoti Sarma, Uday Kulkarni, Parathan Karunakaran, Shuvadeep Ganguly, Prasanth Ganesan, Rajeev Lk, Sharat Damodar, Rajan Kapoor, Rasmi Palassery, Unni Krishnan, Reshma Roshan, Aakash Chozakade, Aravind D, Prasanna Samuel, Om Prakash, Vikram Mathews, Manju Sengar

Blood (2024) 144 (Supplement 1): 5858.

https://doi.org/10.1182/blood-2024-207077

Published: 2024

Journal Articles

Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Chirag Trivedi, Sujith Kumar, Sushil Selvarajan, Sharon Anbumalar Lionel, Anup J Devasia, Fouzia N., Uday Kulkarni, Aby Abraham, Alok Srivastava, Biju George, Vikram Mathews, Anu Korula

Blood (2024) 144 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2024-198979

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium

Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival

Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Clinico-pathological profile and treatment patterns of immune mediated aplastic anemia in resource constrained settings – an analysis from the aplastic anemia registry of India

Higher busulfan cumulative exposure predicts better thalassemia-free survival in patients with beta thalassemia undergoing HCT with busulfan-cyclophosphamide containing conditioning regimen

Long-term imatinib therapy leads to significant reduction in GFR

Role of fludarabine exposure on post-transplant outcomes in high-risk β-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose Intensification

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

EASIX d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Patterns of Care and Outcomes of Adults ≥ 40 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Multicenter Registry Analysis from India

Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only